AI Article Synopsis
- The study investigated the effectiveness of weekly nanoparticle albumin-bound paclitaxel (Nab-PTX) at a dose of 100 mg/m for treating HER2-negative breast cancer in patients with stages II to IV.
- A total of 66 patients participated, showing a 59.1% overall response rate after treatment, with a notable difference in responses between hormone receptor-positive (63.6%) and triple-negative tumors (36.4%).
- Despite some side effects, including peripheral neuropathy and leukocytopenia, Nab-PTX was generally well tolerated, indicating it could be a beneficial neoadjuvant therapy option.
Article Abstract
Background: Taxanes are among the key drugs for breast cancer treatment. This study aimed to evaluate the efficacy of upfront weekly nanoparticle albumin-bound paclitaxel (Nab-PTX; 100 mg/m) for human epidermal growth factor 2 (HER2)-negative breast cancer.
Patients And Methods: Patients with stage II to IV breast cancer received 12 cycles of weekly 100 mg/m Nab-PTX as first-line treatment. Preoperative chemotherapy with anthracyclines after Nab-PTX was recommended.
Results: From 2012 to 2014, we enrolled 66 patients. The overall response rate after Nab-PTX was 59.1% [95% confidence interval(CI)=47.2% to 71.0%), 63.6% in those with hormone receptor-positive tumors, and 36.4% in those with triple-negative tumors. The pathological complete response rate at surgery was 15% (95% CI=6.1% to 24.4%). Toxicity analysis showed grade 2 peripheral neuropathy in 38 patients (57.6%), grade 2/3 leukocytopenia in 29 (43.9%) and grade 2/3 liver dysfunction in five (7.5%).
Conclusion: Weekly neoadjuvant Nab-PTX at 100 mg/m led to good response rates (59.1%) and was well tolerated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.12104 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing Virtual Follow-Up Care: Realist Evaluation of Experiences and Perspectives of Patients With Breast and Prostate Cancer.
J Med Internet Res
January 2025
Cancer Rehabilitation and Survivorship, Department of Supportive Care, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Background: Virtual follow-up (VFU) has the potential to enhance cancer survivorship care. However, a greater understanding is needed of how VFU can be optimized.
Objective: This study aims to examine how, for whom, and in what contexts VFU works for cancer survivorship care.
Hormonal disorders in autism spectrum disorders.
Horm Mol Biol Clin Investig
January 2025
Department of Biochemistry, Faculty of Medicine, 37555 Urmia University of Medical Sciences, Urmia, Iran.
Autism spectrum disorder (ASD) is a pervasive neurobehavioral condition characterized by disruption of behavioral and emotional patterns in individuals with this condition. Given that various environmental and genetic factors play a fundamental role in the pathophysiology of ASD, it can be said that ASD is a multifaceted disease. This study used scientific databases including Google Scholar, PubMed, Scopus, and Semantic Scholar.
View Article and Find Full Text PDFMonocyte-cancer cell fusion is mediated by phosphatidylserine-CD36 receptor interaction and induced by ionizing radiation.
PLoS One
January 2025
Division of Cell- and Neurobiology, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Emerging evidence suggests that fusion of cancer cells with leucocytes, such as macrophages, plays a significant role in cancer metastasis and results in tumor hybrid cells that acquire resistance to chemo- and radiation therapy. However, the precise mechanisms behind the leukocyte-cancer cell fusion remain unclear. The present in vitro study explores the presence of fusion between the monocyte cell line (THP-1) and the breast cancer cell line (MCF-7) in relation to the expression of CD36 and phosphatidylserine with and without treatment of these cells with ionizing radiation.
View Article and Find Full Text PDFQuantitative expression of estrogen, progesterone and human epidermal growth factor receptor-2 and their correlation with immunohistochemistry in breast cancer at Uganda Cancer Institute.
PLoS One
January 2025
Department of Clinical Support Services, Division of Laboratory and Pathology Medicine, Uganda Cancer Institute, Kampala, Uganda.
The detection of Estrogen Receptor (ER), Progesterone Receptor (PR), and Human epidermal growth factor receptor 2 (HER-2) is important for the stratification of breast cancer and the selection of therapeutic modalities. This study aimed to determine the quantitative expression of ER, PR and HER-2 using Immunohistochemistry and their correlation with quantitative baseline Ct values measured using Quantitative Polymerase Chain Reaction (PCR). This study also assessed the use of fresh breast tissue biopsies preserved in RNAlater solution in the quantitative detection of these receptors using PCR technique.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!